HUMAN IPSC-BASED MODEL OF GATA2 DEFICIENCY REVEALS IMPAIRED ENDOTHELIAL-HEMATOPOIETIC DEVELOPMENT

EHA Library, Alessandra Giorgetti, 294996

TRANSCRIPTIONAL REGULATION OF HEMATOPOIETIC STEM CELLS IN AGING AND MYELODYSPLASTIC SYNDROME REVEALS DDIT3 AS A POTENTIAL DRIVER OF TRANSFORMATION

EHA Library, Teresa Ezponda, 294997

COMBINED COHESIN-RUNX1 DEFICIENCY SYNERGISTICALLY PERTURBS CHROMATIN LOOPING AND CAUSES MYELODYSPLASTIC SYNDROMES

EHA Library, Yotaro Ochi, 294998

DISTINCT PATHOGENESIS OF CLONAL HEMATOPOIESIS REVEALED BY HIGH THROUGHPUT SINGLE CELL RNA SEQUENCING INTEGRATED WITH HIGHLY SENSITIVE GENOTYPING METHOD.

EHA Library, Masahiro Nakagawa, 294999

A PHASE III PLACEBO-CONTROLLED TRIAL OF CC-486 IN PATIENTS WITH RED BLOOD CELL TRANSFUSION-DEPENDENT (RBC-TD) ANEMIA AND THROMBOCYTOPENIA DUE TO IPSS LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS)

EHA Library, Guillermo Garcia-Manero, 295000

APR-246 COMBINED WITH AZACITIDINE IN TP53 MUTATED MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA. A PHASE 2 STUDY BY THE GROUPE FRANCOPHONE DES MYÉLODYSPLASIES (GFM)

EHA Library, Thomas Cluzeau, 295001

PHASE 2 STUDY OF PEVONEDISTAT + AZACITIDINE VERSUS AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES/CHRONIC MYELOMONOCYTIC LEUKEMIA OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA

EHA Library, Lionel ADES, 295002

TREATMENT WITH IMETELSTAT PROVIDES DURABLE TRANSFUSION INDEPENDENCE (TI) IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER RISK MDS (LR-MDS) RELAPSED/REFRACTORY (R/R) TO ERYTHROPOIESIS STIMULATING AGENTS (ESA)

EHA Library, Uwe Platzbecker, 295003

RANDOMIZED OPEN-LABELED ACADEMIC TRIAL COMPARING ‘G-CSF PRIOR AZA' WITH STANDARD AZA THERAPY IN HIGH RISK MDS PATIENTS.

EHA Library, Tomas Stopka, 295004

ANTI-TIM-3 ANTIBODY MBG453 IN COMBINATION WITH HYPOMETHYLATING AGENTS (HMAS) IN PATIENTS (PTS) WITH HIGH-RISK MYELODYSPLASTIC SYNDROME (HR-MDS) AND ACUTE MYELOID LEUKEMIA (AML): A PHASE 1 STUDY

EHA Library, Uma Borate, 295005

GENETIC AND CLINICAL RISK PREDICTION IN CHRONIC MYELOMONOCYTIC LEUKEMIA UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION

EHA Library, Nico Gagelmann, 295006

THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IS WELL-TOLERATED AND EFFECTIVE IN MDS PATIENTS: PHASE 1B RESULTS

EHA Library, Sallman David, 295007

A PHASE 1B STUDY EVALUATING THE SAFETY AND EFFICACY OF VENETOCLAX IN COMBINATION WITH AZACITIDINE FOR THE TREATMENT OF RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME

EHA Library, Amer M. Zeidan, 295008

DEFECTIVE GRANULOPOIESIS IN CONGENITAL NEUTROPENIA IS CAUSED BY THE INABILITY OF G-CSF TO INDUCE GADD45Β-MEDIATED GENE DEMETHYLATION AND ACTIVATION OF RETINOIC ACID SIGNALING

EHA Library, Perihan Mir, 295010

PERSISTENCE OF PNH CLONES OVER TIME: INSIGHTS FROM THE MID-TERM ANALYSIS OF THE FRENCH NATION-WIDE MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY

EHA Library, Orianne Wagner-Ballon, 295011

RESULTS OF THE PEGASUS PHASE III RANDOMIZED TRIAL DEMONSTRATING SUPERIORITY OF THE C3 INHIBITOR, PEGCETACOPLAN, COMPARED TO ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Peter Hillmen, 295012

RELAPSE AND CLONAL EVOLUTION IN SEVERE APLASTIC ANEMIA PATIENTS TREATED WITH IMMUNOSUPPRESSION AND ELTROMBOPAG

EHA Library, Bhavisha Patel, 295013

GENETIC SCREENING OF CHILDREN WITH BONE MARROW FAILURE: THE ROLE OF PRIMARY IMMUNE-DEFICIENCIES

EHA Library, Maurizio Miano, 295014

LARGE SCALE WHOLE GENOME PROFILING OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS IDENTIFIES GENOMICALLY DEFINED ULTRA-LOW RISK GROUP

EHA Library, Mehmet Samur, 295015

THE SEARCH FOR OPTIMIZATION STRATEGIES OF MCL-1 INHIBITORS IN MULTIPLE MYELOMA HIGHLIGHTS CONCURRENT BCL-XL TARGETING AND ABCB1 BLOCKADE AS PROMISING THERAPEUTIC STRATEGIES

EHA Library, Arnold Bolomsky, 295016

SINGLE CELL TRANSCRIPTOMIC ANALYSIS OF THE MULTIPLE MYELOMA BONE MARROW IDENTIFIES A UNIQUE INFLAMMATORY STROMAL CELL POPULATION ASSOCIATED WITH MYELOMA CELLS IN-SITU

EHA Library, Tom Cupedo, 295017

CC-93269, A 2+1 T CELL ENGAGER (TCE) TARGETING B-CELL MATURATION ANTIGEN (BCMA) AND CD3Ε, SHOWS ANTITUMOR ACTIVITY IN MULTIPLE MYELOMA PRECLINICAL MODELS

EHA Library, Isaac Boss, 295018

CHARACTERIZATION AND COMPARISON OF MYC REARRANGEMENTS IN PATIENTS WITH MULTIPLE MYELOMA AND OTHER MATURE B-CELL NEOPLASMS

EHA Library, Sonja Seliger, 295019

IXAZOMIB VS PLACEBO AS POST-INDUCTION MAINTENANCE THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS (PTS) NOT UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT (ASCT): PHASE 3 TOURMALINE-MM4 TRIAL

EHA Library, Lawrence Radford, 295020

PRIMARY ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)

EHA Library, Saad Z. Usmani, 295021

IXAZOMIB WITH EITHER DEXAMETHASONE, CYCLOPHOSPHAMIDE-DEXAMETHASONE, THALIDOMIDE-DEXAMETHASONE OR BENDAMUSTINE-DEXAMETHASONE FOLLOWED BY IXAZOMIB MAINTENANCE IN ELDERLY NEWLY DIAGNOSED MYELOMA PATIENTS

EHA Library, Roberto Mina, 295022

BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED, TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA

EHA Library, Hartmut Goldschmidt, 295023

DEPTH OF RESPONSE TO ISATUXIMAB, CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (ISA-KRD) IN FRONT-LINE TREATMENT OF HIGH-RISK MULTIPLE MYELOMA: INTERIM ANALYSIS OF THE GMMG-CONCEPT TRIAL

EHA Library, Katja Weisel, 295024

INTERIM RESULTS FROM THE FIRST PHASE 1 CLINICAL STUDY OF THE B-CELL MATURATION ANTIGEN (BCMA) 2+1 T CELL ENGAGER (TCE) CC-93269 IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Luciano J. Costa, 295025

A PHASE 1 STUDY OF TECLISTAMAB, A HUMANIZED B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, María-Victoria Mateos, 295026

MRD EVALUATION BY PET/CT ACCORDING TO DEAUVILLE CRITERIA COMBINED WITH BONE MARROW TECHNIQUES IN NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS ENROLLED IN THE PHASE II FORTE TRIAL

EHA Library, Elena Zamagni, 295027

FIRST-IN-HUMAN PHASE 1 STUDY OF THE NOVEL CELMOD AGENT CC-92480 COMBINED WITH DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, PAUL RICHARDSON, 295028

IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121), A BCMA-TARGETED CAR T CELL THERAPY, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: INITIAL KARMMA RESULTS

EHA Library, Jesus San Miguel, 295029

SINGLE-CELL MULTI-OMICS REVEALS ABERRANT MEGAKARYOCYTE-PROGENITOR (MKP) SUB-FRACTIONS IN MYELOFIBROSIS (MF) AND IDENTIFIES MUTANT CLONE-SPECIFIC TARGETS

EHA Library, Bethan PSAILA, 295030

RAS/MAPK PATHWAY MUTATIONS ARE ASSOCIATED WITH ADVERSE SURVIVAL OUTCOMES AND MAY PREDICT RESISTANCE TO JAK INHIBITORS IN MYELOFIBROSIS

EHA Library, Giacomo Coltro, 295031

ONCOGENIC KRAS-G12D CAUSES MYELOPROLIFERATION VIA NLRP3 INFLAMMASOME ACTIVATION

EHA Library, Shaima'a Hamarsheh, 295032

EXOME SEQUENCING OF PAIRED MPN AND BLAST PHASE SHOWS AN ACCUMULATION OF SPLICING AND CHROMATIN MODIFYING GENE MUTATIONS, CLONAL EVOLUTION AND GAIN OF RAS PATHWAY MUTATIONS DURING PROGRESSION

EHA Library, Manja Meggendorfer, 295033

PREDICTING THE LONG-TERM EFFICACY OF IFNΑ IN JAK2V617F AND CALR-MUTATED MPN PATIENTS

EHA Library, Amandine Tisserand, 295034

KRT‑232, A FIRST‑IN‑CLASS, MURINE DOUBLE MINUTE 2 INHIBITOR (MDM2I), FOR MYELOFIBROSIS (MF) RELAPSED OR REFRACTORY (R/R) TO JANUS‑ASSOCIATED KINASE INHIBITOR (JAKI) TREATMENT (TX)

EHA Library, Haifa Kathrin Al-Ali, 295035

ADDITION OF PARSACLISIB, A PI3KDELTA INHIBITOR, IN PATIENTS (PTS) WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB (RUX): A PHASE 2 STUDY IN PTS WITH MYELOFIBROSIS (MF)

EHA Library, Abdulraheem Yacoub, 295036

RUXOLITINIB DISCONTINUATION SYNDROME: INCIDENCE, RISK FACTORS AND MANAGEMENT IN 242 PATIENTS WITH MYELOFIBROSIS

EHA Library, Francesca Palandri, 295037

UPDATED RESULTS FROM A PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP, A CD123-TARGETED THERAPY, IN PATIENTS WITH POOR-RISK MYELOFIBROSIS

EHA Library, Naveen Pemmaraju, 295038

EFFICACY AND SAFETY OF MEPOLIZUMAB IN HYPEREOSINOPHILIC SYNDROME: A PHASE III, RANDOMIZED, PLACEBO-CONTROLLED TRIAL

EHA Library, Florence Roufosse, 295039

PET-2-GUIDED ESCALATED BEACOPP FOR PATIENTS WITH ADVANCED NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA: AN ANALYSIS FROM THE GERMAN HODGKIN STUDY GROUP

EHA Library, Dennis A. Eichenauer, 295040

CONDITIONAL RELATIVE SURVIVAL IN ADULT PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: A NATIONWIDE, POPULATION-BASED STUDY IN THE NETHERLANDS, 1989-2017

EHA Library, Julia Driessen, 295041

PET-GUIDED TREATMENT IN PATIENTS WITH ADVANCED-STAGE HODGKIN LYMPHOMA: FOLLOW-UP ANALYSIS OF PET-2-NEGATIVE PATIENTS IN THE HD18 TRIAL BY THE GERMAN HODGKIN STUDY GROUP.

EHA Library, Stefanie Kreissl, 295042

PRIMARY THERAPY AND RELATIVE SURVIVAL IN PATIENTS AGED 60 YEARS AND OLDER WITH CLASSICAL HODGKIN LYMPHOMA: A NATIONWIDE, POPULATION-BASED STUDY IN THE NETHERLANDS, 1989-2017

EHA Library, Julia Driessen, 295043

RESPONSE-ADAPTED THERAPY WITH NIVOLUMAB + BRENTUXIMAB VEDOTIN IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH STANDARD-RISK RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 744

EHA Library, Christine Mauz-Körholz, 295044

ASPEN: RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB FOR PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)

EHA Library, Meletios Dimopoulos, 295045

IXAZOMIB, RITUXIMAB AND DEXAMETHASONE (IRD) IN PATIENTS WITH RELAPSED OR PROGRESSIVE WALDENSTROM'S MACROBLOBULINEMIA: FINAL ANALYSIS OF THE HOVON124/ECWM-R2 TRIAL

EHA Library, Marie José Kersten, 295046

REAL-WORLD OUTCOME IN MANTLE CELL LYMPHOMA – A STUDY OF RELATIVE AND OVERALL SURVIVAL IN PATIENTS PRIMARILY TREATED WITH R-BENDAMUSTINE, R-CHOP OR THE NORDIC MCL2 REGIMEN IN SWEDEN 2007-2017

EHA Library, Alexandra Albertsson Lindblad, 295047

IBRUTINIB, VENETOCLAX PLUS OBINUTUZUMAB IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS

EHA Library, Steven Le, 295048

IBRUTINIB COMPARED TO IMMUNO-CHEMOTHERAPY FOR CENTRAL NERVOUS SYSTEM RELAPSE OF MANTLE CELL LYMPHOMA: A REPORT FROM FONDAZIONE ITALIANA LINFOMI (FIL) AND EUROPEAN MANTLE CELL LYMPHOMA NETWORK (EMCLN)

EHA Library, Chiara Rusconi, 295049

ROLE OF RADIOTHERAPY AND DOSE-DENSIFICATION OF R-CHOP IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA: A SUBGROUP ANALYSIS OF THE UNFOLDER TRIAL OF THE GERMAN LYMPHOMA ALLIANCE (GLA)

EHA Library, Gerhard Held, 295050

QUANTITATIVE PARAMETERS FROM INTERIM PET/CT AFTER TWO R-CHOP14 CYCLES IDENTIFY POOR-RISK DLBCL PATIENTS: RESULTS FROM THE PROSPECTIVE SAKK38/07 CLINICAL STUDY

EHA Library, Emanuele Zucca, 295051

INOTUZUMAB OZOGAMICIN PLUS R-CVP IS A FEASIBLE AND EFFECTIVE REGIMEN FOR FRONTLINE TREATMENT OF DLBCL IN PATIENTS WHO ARE UNFIT FOR R-CHOP: RESULTS OF A RANDOMISED PHASE 2 UK NCRI TRIAL

EHA Library, Elizabeth Phillips, 295052

INITIAL RESULTS OF A PHASE 2 STUDY OF LONCASTUXIMAB TESIRINE, A NOVEL PYRROLOBENZODIAZEPINE-BASED ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Carmelo Carlo-Stella, 295053

EFFICACY AND SAFETY OF ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMAS: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA

EHA Library, Charles Herbaux, 295054

OUTCOME OF LIMITED STAGE PERIPHERAL T-CELL LYMPHOMA AFTER CHOP(-LIKE) THERAPY: A POPULATION BASED STUDY OF 251 PATIENTS FROM THE NORDIC LYMPHOMA EPIDEMIOLOGY GROUP

EHA Library, Ahmed Ludvigsen Al-Mashhadi, 295055

HIGH DOSE METHOTREXATE CNS PROPHYLAXIS IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A MULTICENTRE ANALYSIS OF TOXICITY AND IMPACT ON R-CHOP DELIVERY

EHA Library, Matthew Wilson, 295056

CONDITIONAL RELATIVE SURVIVAL OF ADULT PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN THE RITUXIMAB ERA: A NATIONWIDE, POPULATION-BASED STUDY IN THE NETHERLANDS, 2003-2017

EHA Library, Mujde Durmaz, 295057

RE-MIND STUDY: COMPARISON OF TAFASITAMAB + LENALIDOMIDE (L-MIND) VS LENALIDOMIDE MONOTHERAPY (REAL-WORLD DATA) IN TRANSPLANT-INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Pier Luigi Zinzani, 295058

CHARACTERISTICS AND OUTCOMES OF HIV-RELATED BURKITT LYMPHOMA (HIV-BL) IN THE POST-RITUXIMAB ERA ACROSS 30 US CANCER CENTERS

EHA Library, Juan Pablo Alderuccio, 295059

PHASE 1 ALEXANDER STUDY OF AUTO3 THE FIRST BICISTRONIC CHIMERIC ANTIGEN RECEPTOR (CAR) TARGETING CD19 AND CD22 WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA

EHA Library, Wendy Osborne, 295060

EFFICACY AND SAFETY OF SEQUENTIAL ADMINISTRATION OF CAR T CELLS TARGETING DIFFERENT B CELL ANTIGEN IN CHILDREN WITH REFRACTORY/RELAPSED BURKITT LYMPHOMA

EHA Library, Ying Liu, 295062

OUTCOME OF HIGH-GRADE LYMPHOMA PATIENTS TREATED WITH CD19 CAR-T – UPDATED REAL-WORLD EXPERIENCE IN THE UK

EHA Library, Andrea Kuhnl, 295063

LISOCABTAGENE MARALEUCEL FOR TREATMENT OF SECOND-LINE TRANSPLANT NONELIGIBLE RELAPSED/REFRACTORY AGGRESSIVE LARGE B-CELL NON-HODGKIN LYMPHOMA: UPDATED RESULTS FROM THE PILOT STUDY

EHA Library, Nilanjan Ghosh, 295064

GENOMIC AND EPIGENOMIC INSIGHTS INTO THE ORIGIN, PATHOGENESIS AND CLINICAL BEHAVIOR OF MANTLE CELL LYMPHOMA SUBTYPES

EHA Library, Silvia Bea, 295065

INTEGRATIVE ANALYSIS OF THE GENOMIC LANDSCAPE OF HODGKIN LYMPHOMA USING LIQUID BIOPSIES

EHA Library, Sven Borchmann, 295066

SHMT2 CONTROLS BURKITT LYMPHOMA CELL SURVIVAL BY MAINTAINING ONCOGENIC TCF3 FUNCTION

EHA Library, Anne Christine Wilke, 295067

BASELINE TP53 MUTATIONS AND MOLECULAR REMISSION ARE BIOMARKERS OF RESPONSE TO TREATMENT WITH IBRUTINIB PLUS NIVOLUMAB IN RELAPSED/REFRACTORY DLBCL

EHA Library, Alessio Bruscaggin, 295068

PREDICTING PEMBROLIZUMAB RESPONSE BY HIGHLY MULTIPLEXED TUMOR IMAGING

EHA Library, Christian Schürch, 295069

CLONAL DYNAMICS AND GENOMIC INTEGRITY OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN HUMAN ALLOGENEIC TRANSPLANT RECIPIENTS

EHA Library, Mirjam Belderbos, 295070

IMPACT OF CONDITIONING INTENSITY AND GENOMICS ON RELAPSE AFTER ALLOGENEIC TRANSPLANTATION FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME

EHA Library, Christopher Hourigan, 295071

PATIENTS' CYTOTOXICITY AGAINST MSC AS BIOMARKER TO IDENTIFY RESPONDING PATIENTS IN GRAFT-VERSUS-HOST DISEASE

EHA Library, Antonio Galleu, 295072

COMBINED TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE USING REGULATORY T CELLS AND RUXOLITINIB

EHA Library, Virginia Escamilla Gómez, 295073

ARSENIC TRIOXIDE ALLEVIATES ACUTE GRAFT-VERSUS-HOST DISEASE BY MODULATING MACROPHAGE POLARIZATION

EHA Library, Xiao Liu, 295074

RUXOLITINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE: OVERALL RESPONSE RATE BY BASELINE CHARACTERISTICS IN THE RANDOMIZED PHASE 3 REACH2 TRIAL

EHA Library, Robert Zeiser, 295075

GRAVITAS-301: A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF ITACITINIB OR PLACEBO IN COMBINATION WITH CORTICOSTEROIDS FOR INITIAL TREATMENT OF PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE

EHA Library, Robert Zeiser, 295076

PROGNOSTIC FACTORS AND LONG-TERM FOLLOW-UP OF BASILIXIMAB FOR STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE: UPDATED EXPERIENCES FROM A LARGE-SCALE STUDY

EHA Library, Si-Ning Liu, 295077

EARLY MEASUREMENT OF ST2 AND REG3 HAS A PREDICTIVE VALUE IN HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRASPLANT CYCLOPHOSPHAMIDE OUTCOME

EHA Library, Marta Fonseca, 295078

DEVELOPMENT AND VALIDATION OF A MACHINE-LEARNING GRADING SYSTEM FOR ACUTE GRAFT-VERSUS-HOST DISEASE

EHA Library, Amin Turki, 295079

LOW-DOSE DECITABINE IMPROVES REFRACTORY PROLONGED ISOLATED THROMBOCYTOPENIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION: A RANDOMIZED MULTICENTER CLINICAL TRIAL

EHA Library, Yue Han, 295080

SINGLE CORD BLOOD TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA PATIENTS AGED 60 YEARS OR OLDER: A RETROSPECTIVE STUDY OF THE JAPAN SOCIETY FOR HEMATOPOIETIC CELL TRANSPLANTATION (JSHCT)

EHA Library, Masamichi Isobe, 295081

NARSOPLIMAB (OMS721) FOR THE TREATMENT OF ADULT HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY

EHA Library, Alessandro Rambaldi, 295082

COMPARISON OF RISK FACTORS AND MORTALITY OF DIFFERENT CYTOMEGALOVIRUS END-ORGAN DISEASES FOLLOWING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, xing-ye meng, 295083

ADOPTIVE IMMUNOTHERAPY WITH REGULATORY AND CONVENTIONAL T CELLS AFFORDS HIGH RATE OF CHRONIC GVHD/RELAPSE-FREE SURVIVAL IN ACUTE MYELOID LEUKEMIA AFTER MYELOABLATIVE HAPLOIDENTICAL TRANSPLANTATION

EHA Library, Antonio Pierini, 295084

OUTCOME OF HAEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN WITH FANCONI ANAEMIA: A STUDY ON BEHALF OF THE EBMT SAAWP AND PDWP

EHA Library, Su Han Lum, 295085

A DOUBLE-INSURANCE DUAL HSCT IN PATIENT WITH THALASSEMIA MAJOR: POST-TRANSPLANT CYCLOPHOSPHAMIDE HAPLO-HSCT FOLLOWED BY UNRELATED CORD BLOOD TRANSPLANTATION

EHA Library, Chunfu Li, 295086

OUTCOME OF T-CELL-REPLETE HAPLOIDENTICAL STEM CELL TRANSPLANTATION IMPROVE WITH TIME IN ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT

EHA Library, Arnon Nagler, 295087

POST-TRANSPLANT CYCLOPHOSPHAMIDE PROVIDES SIMILAR OUTCOMES TO ANTITHYMOCYTE GLOBULIN IN HLA-MATCHED UNRELATED DONOR TRANSPLANTATION

EHA Library, Eolia Brissot, 295088

IMPACT OF DIFFERENT EX VIVO T-CELL DEPLETION STRATEGIES ON OUTCOMES FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION FOR CHILDREN WITH PRIMARY IMMUNODEFICIENCY

EHA Library, Su Han Lum, 295089

EPIGENETIC BLUEPRINT OF HUMAN THYMOPOIESIS REVEALS MOLECULAR MECHANISMS OF STAGE-SPECIFIC TCR ENHANCER ACTIVATION

EHA Library, Agata Cieslak, 295090

THE GERMLINE GATA2 R396Q MISSENSE MUTATION FUNCTIONALLY AND QUALITATIVELY ALTERS HEMATOPOIETIC STEM CELL COMPARTMENT IN MICE.

EHA Library, Laetitia Largeaud, 295091

UROLITHIN-A INDUCED METABOLIC REPROGRAMMING OF HEMATOPOIETIC STEM CELL FUNCTION

EHA Library, Mukul Girotra, 295092

THE MESENCHYMAL STEM CELL NICHE REGULATES THE REDOX BALANCE IN ACUTE MYELOID LEUKEMIA INITIATING CELLS.

EHA Library, Borja Saez, 295093

COMBINED SINGLE-CELL DNA METHYLOME AND TRANSCRIPTOME ANALYSIS FACILITATES DECONVOLUTION OF HEMATOPOIETIC COMMITMENT DECISIONS

EHA Library, Sina Stäble, 295094

MULTIVARIATE SUPERVISED LEARNING OF LISOCABTAGENE MARALEUCEL (LISO-CEL) CAR T CELL PRODUCT AND PATIENT CHARACTERISTICS IDENTIFIES ATTRIBUTES ASSOCIATED WITH CLINICAL ENDPOINTS IN LARGE B-CELL LYMPHOMA

EHA Library, Yue Jiang, 295095

MICRORNA-146A REGULATES IMMUNOTHERAPY INDUCED IMMUNE-RELATED ADVERSE EVENTS IN MICE AND HUMANS

EHA Library, Natalie Köhler, 295096

EX-VIVO HEMATOPOIETIC STEM CELL EXPANSION SYSTEM AS A PLATFORM FOR GENE EDITING

EHA Library, Hans Jiro Becker, 295097